Skip to main content
. Author manuscript; available in PMC: 2016 Aug 2.
Published in final edited form as: Pediatr Clin North Am. 2015 Sep 7;62(6):1531–1549. doi: 10.1016/j.pcl.2015.07.015

Figure 2.

Figure 2

Many preclinical studies are in process as well as phase 2 trials as discussed. OIT will move into phase 3 trials. Other studies have not progressed beyond phase 1 studies due to safety or efficacy concerns. EMP-123, E-coli encapsulated, recombinant Modified Peanut proteins Ara h 1, Ara h 2, Ara h 3.